Ipsos expands pan-cancer testing study to Australia

The monitor measures and tracks the use of pan-cancer tests, which test for a wide range of cancer types. It gathers feedback from medical oncologists and pathologists on topics including awareness and current use of the tests, advantages and disadvantages, and barriers to use.

The study has been running in the US since 2016. In addition to the launch in Australia, further expansion to APAC markets is planned for the coming months, the company said.

Pieter De Richter, head of syndicated real world evidence in APAC/MENA for Ipsos Healthcare, said: “With the launch of the study in Australia, we are now able to provide molecular diagnostics businesses and pharma companies with robust insights into drivers and barriers around the usage of pan-cancer testing panels and detailed usage metrics within this important region.”